21041183

Source:http://linkedlifedata.com/resource/pubmed/id/21041183

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0027651, umls-concept:C0033204, umls-concept:C0078058, umls-concept:C0205217, umls-concept:C0282460, umls-concept:C0332325, umls-concept:C0449258, umls-concept:C0796392, umls-concept:C1135135, umls-concept:C1140680, umls-concept:C1514559
pubmed:issue	21
pubmed:dateCreated	2010-11-2
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00696670
pubmed:abstractText	This phase II trial evaluated bevacizumab plus erlotinib in platinum-resistant ovarian cancer; exploratory biomarker analyses, including that of tumor vascular endothelial growth factor A (VEGF-A), were also done.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA023074
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Platinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/VEGFA protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab, http://linkedlifedata.com/resource/pubmed/chemical/erlotinib
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1078-0432
pubmed:author	pubmed-author:AlbertsDavid SDS, pubmed-author:BakerAmanda FAF, pubmed-author:BrewerMolly AMA, pubmed-author:ChambersSetsuko KSK, pubmed-author:ClouserMary CMC, pubmed-author:CohenJanice LJL, pubmed-author:CuiHaiyanH, pubmed-author:GordonAlan NAN, pubmed-author:GordonMichael SMS, pubmed-author:HatchKenneth DKD, pubmed-author:IsaacsJeffrey DJD, pubmed-author:JanicekMike FMF, pubmed-author:NagleRaymond BRB, pubmed-author:RoeDenise JDJ, pubmed-author:WrightHeather MHM
pubmed:copyrightInfo	©2010 AACR.
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	16
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	5320-8
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:21041183-Antibodies, Monoclonal, pubmed-meshheading:21041183-Antibodies, Monoclonal, Humanized, pubmed-meshheading:21041183-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21041183-Carcinoma, pubmed-meshheading:21041183-Disease Progression, pubmed-meshheading:21041183-Disease-Free Survival, pubmed-meshheading:21041183-Drug Resistance, Neoplasm, pubmed-meshheading:21041183-Female, pubmed-meshheading:21041183-Gene Expression Regulation, Neoplastic, pubmed-meshheading:21041183-Humans, pubmed-meshheading:21041183-Likelihood Functions, pubmed-meshheading:21041183-Ovarian Neoplasms, pubmed-meshheading:21041183-Platinum Compounds, pubmed-meshheading:21041183-Prognosis, pubmed-meshheading:21041183-Quinazolines, pubmed-meshheading:21041183-Treatment Outcome, pubmed-meshheading:21041183-Tumor Microenvironment, pubmed-meshheading:21041183-Up-Regulation, pubmed-meshheading:21041183-Vascular Endothelial Growth Factor A
pubmed:year	2010
pubmed:articleTitle	Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
pubmed:affiliation	Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724-5024, USA. schambers@azcc.arizona.edu
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Research Support, N.I.H., Extramural